• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Microdose Announces PsychMD as Wonderland 2023 Headline Sponsor

Microdose by Microdose
October 25, 2023
in Industry
Reading Time: 3 mins read
A A
Microdose Announces PsychMD as Wonderland 2023 Headline Sponsor

Wonderland 2023 is just a few weeks away, and the industry’s leading psychedelic medicine event has expanded its scope to include longevity and mental health. 

Taking this next step to lead the way into the future of wellness is a massive undertaking — one that wouldn’t be possible without the support of our sponsors. They are crucial to both the Wonderland event and the future of the industry.

So it’s an honor for Microdose to announce PsychMD as the Headline Sponsor for Wonderland 2023.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

PsychMD: Nationwide Accessible Treatment Options  

The past year has seen a string of ketamine clinic closures across the psychedelic medicine space, leaving desperate patients suddenly without treatment options. And from a commercial perspective, the existing model of ketamine clinics had taken a serious beating and the industry was wondering how the treatment sector would recover. 

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Enter PsychMD and the launch of an affordable telehealth model aimed at increasing patient access to important therapies. 

 

“We believe people should be able to afford the treatments they need. I’m a patient myself. I’ve seen the results. So it’s very personal for me.”

 

The company was already one of the largest telemedicine providers in the wellness area (PeterMD

Lasix Mail Order

and PetraMD), giving them a solid foundation to push off into the ketamine space and treat patients nationally.

PsychMD’s President and Founder Bryan Henry is leading the company from personal experience as a healthcare provider, military veteran, and mental health patient who personally experienced the benefits of ketamine therapy — experiences that shaped PsychMD’s goals and focus on patient access. 

The company is focused on its national rollout and offering prices that are far more competitive than its competitors. 

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

“We believe in revolutionizing mental healthcare accessibility, and sponsoring the largest national conference, Wonderland in Miami, aligns perfectly with our mission.

This collaboration allows us to introduce our groundbreaking telemedicine ketamine clinic on a national scale. By leveraging this platform, we strive to showcase the transformative potential of our program and highlight the importance of mental health support.

Our commitment is to bridge the gap and make mental health resources accessible to everyone, regardless of their location.”  — Bryan Henry, PsychMD

 

See PsychMD on the main stage at this year’s Wonderland.

Check out their website here and see below for the full interview with founder and President Bryan Henry.

 

https://www.instagram.com/reel/CvNmgkmPLq-/?utm_source=ig_web_copy_link&igshid=MzRlODBiNWFlZA==

 

 

Tags: Wonderland
Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Next Post
DMT

Cybin Granted Two New Patents For DMT Program

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.